Amarin reported Q4 2025 total net revenue of USD 49.2 million (down 21%), including net product revenue of USD 46.5 million (down 23%) and licensing and royalty revenue of USD 2.7 million (up 20%). Q4 operating loss narrowed to USD 6.3 million from USD 52.5 million, while net loss improved to USD 1.2 million from USD 48.6 million. Cash and investments were USD 302.6 million at December 31, 2025, and the company said it remained debt free. By geography in Q4, U.S. net product revenue was USD 41.1 million (down 7%), Europe was USD 2.3 million (down 42%), and rest-of-world was USD 3.1 million (down 74%). Amarin attributed the revenue decline primarily to lower rest-of-world sales following a USD 7.8 million stocking order in the prior-year quarter, a decline in U.S. net selling price, and the transition of European sales activities to Recordati under the long-term licensing agreement announced in June 2025. Q4 operating expenses were USD 29.5 million (down 31%), including SG&A of USD 20.1 million, R&D of USD 5.4 million, and restructuring expense of USD 4.1 million tied to the Global Restructuring Plan associated with the Recordati licensing agreement, which included eliminating commercial roles in Europe. For FY 2025, Amarin reported total net revenue of USD 213.6 million and a net loss of USD 38.8 million, and said it supported a total of 45 publications in 2025 related to the VASCEPA/VAZKEPA (icosapent ethyl) evidence base.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602250700PRIMZONEFULLFEED9661006) on February 25, 2026, and is solely responsible for the information contained therein.
Comments